SERB Pharmaceuticals acquires Y-mAbs for $412M ($8.60/share); 105% premium

Y-mAbs Therapeutics, Inc.

All-cash tender offer at $8.60/share (~$412M equity value), 105% premium to Y-mAbs' Aug 4 close.
SERB to commence tender offer no later than August 19, 2025; closing subject to conditions.
Deal includes Y-mAbs' lead asset DANYELZA (naxitamab-gqgk) for neuroblastoma; Board unanimously approved.
Supporting stockholders (~16% of shares) have agreed to tender shares in support of the deal.
Termination fee of $14.25M payable by Y-mAbs under certain circumstances; no financing condition.

item 1.01item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.